Campto (UK), Camptosar
Pharmacologic class: Topoisomerase inhibitor
Therapeutic class: Hormonal antineoplastic
Pregnancy risk category D
Inhibits topoisomerase 1 (an enzyme that allows DNA replication) by binding to it. This action prevents religation of DNA strand, which results in breakage of double-stranded DNA and cell death.
Injection: 20 mg/ml in 2-ml and 5-ml vials
⊘Indications and dosages
➣ Metastatic colorectal cancer or recurrence or progression of metastatic colorectal cancer after fluorouracil (5-FU) therapy
Adults: 125 mg/m2 I.V. infused over 90 minutes on days 1, 8, 15, and 22, followed by a 2-week rest; given with leucovorin and 5-FU. Or, 180 mg/m2 I.V. infused over 90 minutes on days 1, 15, and 29 with leucovorin, 5-FU bolus, and 5-FU infusion followed by a 2-week rest. Or as monotherapy, 125 mg/m2 I.V. infused over 90 minutes weekly for 4 weeks, followed by a 2-week rest period; or, 350 mg/m2 I.V. infused over 90 minutes q 3 weeks as long as tolerable. Adjust dosage in increments based on tolerance and age.
• Most cancers
• Hypersensitivity to drug
• Concurrent atazanavir use
• Pregnancy or breastfeeding
Use cautiously in:
• bone marrow depression, severe diarrhea
• patients undergoing radiation therapy
• elderly patients
☞ Follow facility policy for handling antineoplastics. If skin contact occurs, wash with soap and water immediately and thoroughly. If mucous membrane contact occurs, flush with water.
• Dilute in dextrose 5% in water or normal saline solution, to a concentration of 0.12 to 1.1 mg/ml.
• Infuse within 6 hours if drug is stored at room temperature or within 24 hours if refrigerated.
• Give single dose by I.V. infusion over 90 minutes.
• Administer antiemetic to ease nausea and vomiting, as needed and prescribed.
CNS: insomnia, dizziness, asthenia, headache, akathisia
CV: vasodilation, orthostatic hypotension
GI: nausea, vomiting, constipation, diarrhea, flatulence, dyspepsia, abdominal pain or enlargement, stomatitis, anorexia
Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia
Musculoskeletal: back pain
Respiratory: dyspnea, increased cough
Skin: alopecia, diaphoresis, rash
Other: weight loss, edema, fever, pain, chills, minor infections
Drug-drug.Dexamethasone: increased risk of lymphocytopenia
Diuretics: increased risk of dehydration
Laxatives: increased risk of diarrhea
Other antineoplastics: additive adverse effects
Drug-diagnostic tests.Alkaline phosphatase: increased level
Hemoglobin, neutrophils, white blood cells: decreased values
☞ Assess CBC before each infusion. Withhold dose if neutrophil count is below 1,500 cells/mm3.
• Monitor infusion site for extravasation; if it occurs, flush with sterile water and apply ice.
• Assess fluid intake and output. Keep patient well hydrated.
• Monitor oral intake. Evaluate for nausea and vomiting.
• Assess for diarrhea. In severe diarrhea, expect to decrease dosage or withhold dose.
• Institute infection-control protocols to help prevent infection.
• Monitor liver function test results.
• Inform patient that blood tests will be done before each dose.
• Instruct patient to report pain at infusion site; severe nausea or vomiting; severe, increased, or bloody diarrhea; infection; or injury.
☞ Instruct patient to immediately report unusual tiredness or yellowing of skin or eyes.
• Tell patient that drug increases his risk of infection. Advise him to avoid crowds and other potential infection sources.
• Caution female patient not to breastfeed or become pregnant during therapy. Recommend barrier contraception.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.